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potential for a CHIK virus pandemic. Efforts to monitor the
disease will only provide minimal warning in a global soci-
ety, and steps must be taken to prevent the morbidity and
mortality associated with a possible pandemic. There is no
speciﬁc treatment for Chikungunya virus and there is no
vaccine currently available. We propose a novel consensus-
based approach to vaccine development, employing a DNA
vaccine strategy that can provide more highly cross-reactive
cellular immunity against CHIK virus. The vaccine cassette
was designed based on Capsid (Cap) and Envelope (E1)
speciﬁc consensus sequences with several modiﬁcations,
including codon optimization, RNA optimization, the addi-
tion of a Kozak sequence, and a substituted immunoglobulin
E leader sequence. The expression of Cap and envelope
E1 was evaluated using T7-coupled transcription/translation
and immuno blot analysis. A recently developed, adap-
tive constant-current electroporation technique was used to
immunize mice (both Balb/C & C57BL/6 mice strain) with an
intramuscular injection of plasmid coding for the CHICK-Cap
and E1. We show such constructs can induce strong cellular
immunity against CHIK-Cap and E1 antigens. The analysis
of speciﬁc antibody responses suggested that CHIK-E1 could
induce a strong E1 speciﬁc antibody response. Epitope map-
ping results indicated that there is an increase in the breadth
and magnitude of cross-reactive cellular responses induced
by both the Capsid and Envelope immunogen. These prop-
erties suggest that such a consensus immunogen deserves
further examination for its potential to serve as a component
antigen in a CHIK vaccine cocktail.
doi:10.1016/j.ijid.2008.05.021
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Introduction: A highly attenuated smallpox vaccine,
LC16m8, is generated from parent strain, vaccinia virus Lis-
ter, by passages of Lister in primary rabbit kidney cells at a
temperature of 30 ◦C. LC16m8 lacks expression of the full-
length B5R membrane protein, one of the most important
viral membrane proteins for induction of immune response
to vaccinia virus, due to a frameshift mutation in the gene.
A single vaccination with LC16m8 protects non-human pri-
mates (NHPs) from monkeypox, monkeypox virus infection.
In the present study, the efﬁcacy of LC16m8 as a thera-
peutic vaccine was evaluated in protection of NHPs from
monkeypox.
Materials and Methods: Twenty-two NHPs (Macaca fasci-
cularis) were used. The NHPs were immunized with LC16m8
or mock followed by subcutaneous inoculation of monkey-
pox Zr-599. Three were mock-immunized and infected with
the virus. Three were infected with the virus and then immu-
nized with LC16m8. Three, 3, and 5 NHPs were infected with
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he virus 3, 7, and 14—24 days after vaccination, respec-
ively. Clinical manifestations weremonitored. Viremia level
nd antibody response were determined by the quantita-
ive real-time PCR and IgG-ELISA, respectively. Pathological
xamination was carried out in these subjects.
Results: Post-exposure vaccination with LC16m8 for
HPs, which were infected with monkeypox virus, improved
he clinical manifestation of monkeypox, while all the naive
ubjects were nearly lethal. Vaccination with LC16m8 7 days
efore monkeypox virus challenge completely protected
HPs from monkeypox. Viremia level in the post-exposure
accinated subjects was signiﬁcantly lower than that in the
aive subjects.
Discussion: LC16m8 has been re-produced and stockpiled
n Japan for the possible threat of bioterrorism with variola
irus as a bioweapon. Based on these results, it is suggested
hat LC16m8 may protect humans from smallpox, if they
ere immunized with LC16m8 immediately after the event
f variola virus infection.
oi:10.1016/j.ijid.2008.05.022
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istribution and Genetic Diversity of Plasmodium fal-
iparum Erythrocyte Binding Antigen 175 and Clinical
utcome of Malaria in the Kassena-Nankana District
. Egyir ∗, C. Brown, M. Wilson, K. Koram
Noguchi Memorial Institute for Medical Research, Accra,
hana
The Erythrocyte Binding Antigen 175 (EBA 175) is a
75 kDalton Plasmodium falciparum antigen which plays a
ajor role in erythrocyte recognition by the parasite. It
lso induces antibodies which inhibit merozoite invasion.
BA 175 has been sequenced from FCR-3 and CAMP strains
f Plasmodium falciparum. The sequences were identical in
ost parts of the gene, differences were apparent in the
23bp segment in the FCR-3 strain, the F-genotype, and
he 342bp segment, the C-genotype. Parasite strains pos-
ess either one or the other segment and never both. The
unctions and potential effects of this dimorphism remain
nclear. This study therefore investigated the relationship
etween this dimorphism and clinical outcome of malaria.
nested polymerase chain reaction (PCR) was used to deter-
ine the genotypes of the parasite strains that exhibit this
imorphism in severe, mild and healthy controls of malaria
rom the Kassena Nankana District (KND), an area which
ad been earmarked for future vaccine trial. A total of 299
amples were analysed, 232 of these samples were positive
ith Plasmodium falciparum infections, these comprised 75
32.2%), 76 (32.6%) and 81 (35.5%) samples of severe, mild
nd healthy controls of malaria respectively, were geno-
yped for the EBA-175 gene. The severe samples, had a
istribution of 44 (58.66%), 24 (32%) and 7 (9.3%) of the
, C and CF EBA-175 genes respectively; the mild samples
omprised, 42 (55.3%), 29 (38%), and 5 (6.6%) of the F, C
nd CF EBA-175 genes respectively; the healthy controls:
9 (72%), 21 (26%), and 13 (16%) of the F, C and CF EBA-
75 genes respectively. A chi-square test revealed that the
ixed genotype (CF) is signiﬁcantly associated with severe
alaria (p = 0.04; OR = 8.23, 95% CI = 1.048—64.7), whereas
